The COVID-19 pandemic has drastically slashed company valuations and could potentially prevent a near-time rebound in shares. The coronavirus pandemic is also causing elective procedures to be postponed, which will result in a low-demand for spine procedures.
However, Globus Medical’s operating profile is stronger than its peers, as the company holds $721 million in cash, no debt and a share buyback authorization around $200 million. Because of this excess, BTIG’s Ryan Zimmernan said Globus is in a position to take advantage of the depressed market and buy complementary assets at discounted levels. If Globus does this, BTIG believes the company could still report positive growth figures in 2020.
More articles on orthopedics and spine:
The Joint Commission updates surgery center burden reduction rules
Surglogs hires new director of regulatory compliance
ASC becomes Iowa’s 1st to gain advanced orthopedic certification — 5 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.